
As new medications enter the market, we’ve observed a troubling new trend: an influx of clinically superfluous brand drugs that carry hefty price tags but offer little to no added clinical value.
Recently, manufacturers have launched new brand-name prescription wound dressings that include similar combinations of ingredients as OTC and lower-cost generic products yet are priced far higher than the alternatives — up to 125 times more.
This report shines a spotlight on the latest category: Wound care.
Related content

Case study: Strategic formulary changes

Don't pay 5,000% more for commonly available generic drugs
